Hepatitis B virus reactivation induced by Yttrium-90-ibritumomab-tiuxetan

Leukemia and Lymphoma

Volumn 48, Issue 9, 2007, Pages 1866-1868

  Cil, Timucin ^a   Altintas, Abdullah ^a   Tuzun, Yekta ^a   Pasa, Semir ^a   Isikdogan, Abdurrahman ^a  

^a DICLE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LAMIVUDINE; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AXILLARY LYMPH NODE; CANCER RELAPSE; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FATIGUE; FEVER; FOLLICULAR LYMPHOMA; HEPATITIS B; HISTOPATHOLOGY; HUMAN; LYMPHADENOPATHY; MALE; MULTIPLE CYCLE TREATMENT; NIGHT SWEAT; NONHODGKIN LYMPHOMA; NONHUMAN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; VIRUS ACTIVATION; YTTRIUM RADIOISOTOPES;

EID: 34548591528     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701509848     Document Type: Article

References (15)

1. Harris, N. L., Jaffe, E. S., Stein, H., Banks, P. M., Chan, J. K. and Cleary, M. L. (1995) Lymphoma classification proposal: Clarification. Blood, 85, pp. 857-860.
2. McLaughlin, P., Grillo-Lopez, A. J., Link, B. K., Levy, R., Czuczman, M. S. and Williams, M. E. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol, 16, pp. 2825-2833.
3. Lok, A SF, Lai, C. L. and Wu, P. C. (1987) Hepatitis B virus infection in Chinese families in Hong Kong. Am J Epidemiol, 126, pp. 492-499.
4. Dursun, M., Ertem, M., Yilmaz, S., Gunay, S., Tuncer, O. and Zeynep, S. (2005) Prevalence of hepatitis B infection in the southeastern region of Turkey: Comparison of risk factors for HBV infection in rural and urban areas. Jpn J Infect Dis, 58, pp. 15-19.
5. Steinberg, J. L., Yeo, W., Zhong, S., Chan, J YH, Tam, J. S. and Chan, P KS (2000) Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: Precore/core mutations may play an important role. J Med Virol, 60, pp. 249-255.
6. Yeo, W., Chan, P KS, Zhong, S., Ho, W. M., Steinberg, J. L. and Tam, J. S. (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy. a prospective study of 626 patients with identification of risk factors. J Med Virol, 62, pp. 299-307.
7. Hanson, R. G., Peters, M. G. and Hoofnagle, J. H. (1986) Effects of immunosuppressive therapy with prednisolone on B and T lymphocyte function in patients with chronic type B hepatitis. Hepatology, 6, pp. 173-179.
8. Wands, J. R. (1975) Subacute and chronic active hepatitis after with-drawal of chemotherapy (letter). Lancet, 2, p. 979.
9. Liag, R., Lau, G KK and Kwong, Y. L. (1999) Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis carriers: A review of the problem. J Clin Oncol, 17, pp. 394-398.
10. Borg, F. T., Smorenburg, S., De Man, R. A., Rietbroek, R. C., Chamuleau, R. and Jones, E. A. (1998) Recovery from life-threatening corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy. Dig Dis Sci, 43, pp. 2267-2270.
11. Clark, F. L., Drummond, M. W., Chambers, S., Chapman, B. A. and Patton, W. N. (1998) Successful treatment of lamivudine for fulminant hepatitis B infection following intensive therapy for high grade non-Hodgkin's lymphoma. Ann Oncol, 9, pp. 385-387.
12. Yeo, W., Chan, P KS, Ho, W. M., Zee, B., Lam, K. C. and Lei, K IK (2004) Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol, 22, pp. 927-934.
13. Tsutsumi, Y., Kawamura, T., Saitoh, S., Yamada, M., Obara, S. and Miura, T. (2004) Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: Necessity of prophylaxis for hepatitis virus reactivation in rituximab therapy. Leuk Lymphoma, 45, pp. 627-629.
14. Law, J. K., Ho, J. K., Hoskins, P. J., Erb, S. R., Steinbrecher, U. P. and Yoshida, E. M. (2005) Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: Potential implications for future prophylaxis recommendations. Leuk Lymphoma, 46, pp. 1085-1089.
15. Leonard, J. P. (2005) Targeting CD20 in follicular NHL: Novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates. Hematology, pp. 335-339.